FGF4 alleviates hyperglycemia in diabetes and obesity conditions

Sivaraj M Sundaram; Raji Rajesh Lenin; Rajiv Janardhanan

doi:10.1016/j.tem.2023.08.004

FGF4 alleviates hyperglycemia in diabetes and obesity conditions

Trends Endocrinol Metab. 2023 Oct;34(10):583-585. doi: 10.1016/j.tem.2023.08.004. Epub 2023 Aug 23.

Authors

Sivaraj M Sundaram¹, Raji Rajesh Lenin², Rajiv Janardhanan²

Affiliations

¹ Division of Medical Research, Faculty of Medical and Health Sciences, SRM Institute of Science and Technology, Kattankulathur 603 203, Chengalpattu District, Tamil Nadu, India. Electronic address: mss@srmist.edu.in.
² Division of Medical Research, Faculty of Medical and Health Sciences, SRM Institute of Science and Technology, Kattankulathur 603 203, Chengalpattu District, Tamil Nadu, India.

PMID: 37625920
DOI: 10.1016/j.tem.2023.08.004

Abstract

Increasing evidence suggests that the brain plays a key role in glucose homeostasis, making it a potential target for the treatment of type 2 diabetes (T2D). Sun et al. recently reported that intracerebroventricular (ICV) administration of a single dose of fibroblast growth factor 4 (FGF4) can induce sustained T2D remission in mouse models in the absence of any risk of hypoglycemia.

Keywords: Type-2 diabetes; fibroblast growth factors; glucose-sensitive neurons; hypothalamus.

MeSH terms

Animals
Diabetes Mellitus, Type 2* / drug therapy
Fibroblast Growth Factor 4
Hyperglycemia* / drug therapy
Hypoglycemia*
Mice
Obesity / drug therapy

Substances

Fibroblast Growth Factor 4
Fgf4 protein, mouse